Chemically programmed bispecific antibodies in diabody format

Journal of Biological Chemistry

Volumn 291, Issue 37, 2016, Pages 19661-19673

  Walseng, Even ^a   Nelson, Christopher G ^a   Qi, Junpeng ^a   Nanna, Alex R ^a   Roush, William R ^a   Goswami, Rajib K ^b   Sinha, Subhash C ^b   Burke, Terrence R ^a   Rader, Christoph ^c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; MOLECULES; MONOCLONAL ANTIBODIES; TUMORS;

CANCER IMMUNOTHERAPY; FOLATE RECEPTOR; HEALTHY TISSUES; MONOCLONAL ANTIBODIES (MAB); OVARIAN CANCER CELLS; PROOF OF CONCEPT; SMALL MOLECULES; SYSTEMIC RESPONSE;

ANTIBODIES;

BISPECIFIC ANTIBODY; FARLETUZUMAB; FOLATE RECEPTOR 1; FOLIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY HAPTEN; UNCLASSIFIED DRUG; CANCER ANTIBODY; FOLR1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; EFFECTOR CELL; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; FEMALE; HEK293 CELL LINE; IMMUNOLOGY; OVARY TUMOR; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; FEMALE; FOLATE RECEPTOR 1; HEK293 CELLS; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS;

EID: 84986874421     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.745588     Document Type: Article

References (58)

1. Zhukovsky, E. A., Morse, R. J., and Maus, M. V. (2016) Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr. Opin. Immunol. 40, 24-35
2. Kontermann, R. E., and Brinkmann, U. (2015) Bispecific antibodies. Drug Discov. Today 20, 838-847
3. Frankel, S. R., and Baeuerle, P. A. (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 17, 385-392
4. Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., and Segal, D. M. (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to antitarget cell antibody. Nature 316, 354-356
5. Rader, C. (2014) Chemically programmed antibodies. Trends Biotechnol. 32, 186-197
6. Cui, H., Thomas, J. D., Burke, T. R., Jr, and Rader, C. (2012) Chemically programmed bispecific antibodies that recruit and activate T cells. J. Biol. Chem. 287, 28206-28214
7. Kim, C. H., Axup, J. Y., Lawson, B. R., Yun, H., Tardif, V., Choi, S. H., Zhou, Q., Dubrovska, A., Biroc, S. L., Marsden, R., Pinstaff, J., Smider, V. V., and Schultz, P. G. (2013) Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 17796-17801
8. Kularatne, S. A., Deshmukh, V., Gymnopoulos, M., Biroc, S. L., Xia, J., Srinagesh, S., Sun, Y., Zou, N., Shimazu, M., Pinkstaff, J., Ensari, S., Knudsen, N., Manibusan, A., Axup, J. Y., Kim, C. H., Smider, V. V., Javahishvili, T., and Schultz, P. G. (2013) Recruiting cytotoxic T cells to folate-receptor-positive cancer cells. Angew. Chem. Int. Ed. Engl. 52, 12101-12104
9. Rader, C., Turner, J. M., Heine, A., Shabat, D., Sinha, S. C., Wilson, I. A., Lerner, R. A., and Barbas, C. F. (2003) A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J. Mol. Biol. 332, 889-899
10. Wagner, J., Lerner, R. A., and Barbas, C. F., 3rd (1995) Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 270, 1797-1800
11. Barbas, C. F., 3rd, Heine, A., Zhong, G., Hoffmann, T., Gramatikova, S., Björnestedt, R., List, B., Anderson, J., Stura, E. A., Wilson, I. A., and Lerner, R. A. (1997) Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science 278, 2085-2092
12. Rader, C., Sinha, S. C., Popkov, M., Lerner, R. A., and Barbas, C. F., 3rd (2003) Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci. U.S.A. 100, 5396-5400
13. Li, L. S., Rader, C., Matsushita, M., Das, S., Barbas, C. F., 3rd, Lerner, R. A., and Sinha, S. C. (2004) Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J. Med. Chem. 47, 5630-5640
14. Popkov, M., Rader, C., Gonzalez, B., Sinha, S. C., and Barbas, C. F., 3rd (2006) Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int. J. Cancer 119, 1194-1207
15. Beverley, P. C., and Callard, R. E. (1981) Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur. J. Immunol. 11, 329-334
16. Arnett, K. L., Harrison, S. C., and Wiley, D. C. (2004) Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment. Proc. Natl. Acad. Sci. U.S.A. 101, 16268-16273
17. Rodrigues, M. L., Shalaby, M. R., Werther, W., Presta, L., and Carter, P. (1992) Engineering a humanized bispecific F(abô)2 fragment for improved binding to T cells. Int. J. Cancer Suppl. 7, 45-50
18. Zhu, Z., Lewis, G. D., and Carter, P. (1995) Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells. Int. J. Cancer 62, 319-324
19. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmüller, G., Reinhardt, C., Baeuerle, P. A., and Kufer, P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977
20. Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H. A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Köhne-Volland, R., Brüggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P. A., Kneba, M., Einsele, H., Riethmüller, G., Hoelzer, D., Zugmaier, G., and Bargou, R. C. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498
21. Przepiorka, D., Ko, C. W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H. J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., Mehrotra, N., Ricks, T. K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A. T., and Pazdur, R. (2015) FDA Approval: Blinatumomab. Clin. Cancer Res. 21, 4035- 4039
22. Baeuerle, P. A., and Reinhardt, C. (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941-4944
23. Rader, C. (2011) DARTs take aim at BiTEs. Blood 117, 4403-4404
24. Holliger, P., Prospero, T., and Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 90, 6444- 6448
25. Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., Yang, Y., Jin, L., Ciccarone, V., Moore, P. A., Koenig, S., and Bonvini, E. (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399, 436-449
26. Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., Shah, K., Jin, L., Zhang, S., He, L., Zhang, T., Ciccarone, V., Koenig, S., Bonvini, E., and Johnson, S. (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542-4551
27. Teng, L., Xie, J., and Lee, R. J. (2012) Clinical translation of folate receptortargeted therapeutics. Expert Opin. Drug Deliv. 9, 901-908
28. Xia, W., and Low, P. S. (2010) Folate-targeted therapies for cancer. J. Med. Chem. 53, 6811-6824
29. Vergote, I. B., Marth, C., and Coleman, R. L. (2015) Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34, 41-52
30. Ebel, W., Routhier, E. L., Foley, B., Jacob, S., McDonough, J. M., Patel, R. K., Turchin, H. A., Chao, Q., Kline, J. B., Old, L. J., Phillips, M. D., Nicolaides, N. C., Sass, P. M., and Grasso, L. (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Cancer Immun. 7, 6
31. Kamen, B. A., and Smith, A. K. (2012) Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother. Pharmacol. 70, 113-120
32. Zhu, X., Tanaka, F., Lerner, R. A., Barbas, C. F., 3rd, and Wilson, I. A. (2009) Direct observation of an enamine intermediate in amine catalysis. J. Am. Chem. Soc. 131, 18206-18207
33. De Cesare, M., Calcaterra, C., Pratesi, G., Gatti, L., Zunino, F., Mènard, S., and Balsari, A. (2008) Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin. Cancer Res. 14, 5512-5518
34. Sommariva, M., De Cecco, L., De Cesare, M., Sfondrini, L., Ménard, S., Melani, C., Delia, D., Zaffaroni, N., Pratesi, G., Uva, V., Tagliabue, E., and Balsari, A. (2011) TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res. 71, 6382-6390
35. Linke, R., Klein, A., and Seimetz, D. (2010) Catumaxomab: clinical development and future directions. mAbs 2, 129-136
36. Chichili, G. R., Huang, L., Li, H., Burke, S., He, L., Tang, Q., Jin, L., Gorlatov, S., Ciccarone, V., Chen, F., Koenig, S., Shannon, M., Alderson, R., Moore, P. A., Johnson, S., and Bonvini, E. (2015) A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci. Transl. Med. 7, 289ra282
37. Smith, E. J., Olson, K., Haber, L. J., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., Principio, J., MacDonald, D., Kantrowitz, J., Papadopoulos, N., Stahl, N., Yancopoulos, G. D., Thurston, G., and Davis, S. (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci. Rep. 5, 17943
38. Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., Moessner, E., Ast, O., Bruenker, P., Grau-Richards, S., Schaller, T., et al. (2016) A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin. Cancer Res. 22, 3286-3297
39. Huang, H., Lai, J. Y., Do, J., Liu, D., Li, L., Del Rosario, J., Doppalapudi, V. R., Pirie-Shepherd, S., Levin, N., Bradshaw, C., Woodnutt, G., Lappe, R., and Bhat, A. (2011) Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 17, 1001-1011
40. Low, P. S., and Kularatne, S. A. (2009) Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 13, 256-262
41. Spannuth, W. A., Sood, A. K., and Coleman, R. L. (2010) Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther. 10, 431-437
42. Lorusso, P. M., Edelman, M. J., Bever, S. L., Forman, K. M., Pilat, M., Quinn, M. F., Li, J., Heath, E. I., Malburg, L. M., Klein, P. J., Leamon, C. P., Messmann, R. A., and Sausville, E. A. (2012) Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J. Clin. Oncol. 30, 4011-4016
43. Konner, J. A., Bell-McGuinn, K. M., Sabbatini, P., Hensley, M. L., Tew, W. P., Pandit-Taskar, N., Vander Els, N., Phillips, M. D., Schweizer, C., Weil, S. C., Larson, S. M., and Old, L. J. (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin. Cancer Res. 16, 5288-5295
44. Roy, E. J., Gawlick, U., Orr, B. A., and Kranz, D. M. (2004) Folate-mediated targeting of T cells to tumors. Adv. Drug Deliv. Rev. 56, 1219-1231
45. Kranz, D. M., Patrick, T. A., Brigle, K. E., Spinella, M. J., and Roy, E. J. (1995) Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. U.S.A. 92, 9057-9061
46. Kranz, D. M., Manning, T. C., Rund, L. A., Cho, B. K., Gruber, M. M., and Roy, E. J. (1998) Targeting tumor cells with bispecific antibodies and T cells. J. Control. Release 53, 77-84
47. Thompson, S., Dessi, J., and Self, C. H. (2009) Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as antiovarian cancer therapeutics. mAbs 1, 348-356
48. van Ravenswaay Claasen, H. H., van de Griend, R. J., Mezzanzanica, D., Bolhuis, R. L., Warnaar, S. O., and Fleuren, G. J. (1993) Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int. J. Cancer 55, 128-136
49. Tibben, J. G., Boerman, O. C., Massuger, L. F., Schijf, C. P., Claessens, R. A., and Corstens, F. H. (1996) Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int. J. Cancer 66, 477-483
50. Schreiner, J., Thommen, D. S., Herzig, P., Bacac, M., Klein, C., Roller, A., Belousov, A., Levitsky, V., Savic, S., Moersig, W., Uhlenbrock, F., Heinzelmann-Schwarz, V. A., Umana, P., Pisa, P., Lardinois, D., Müller, P., Karanikas, V., and Zippelius, A. (2016) Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 5, e1062969
51. Zhu, M., Wu, B., Brandl, C., Johnson, J., Wolf, A., Chow, A., and Doshi, S. (2016) Blinatumomab, a Bispecific T-cell Engager (BiTE) for CD-19 Targeted cancer immunotherapy: Clinical pharmacology and its implications. Clin. Pharmacokinet. May 21 [Epub ahead of print].
52. Liu, Y., Goswami, R. K., Liu, C., and Sinha, S. C. (2015) Chemically programmed bispecific antibody targeting Legumain protease and αvoβ3 integrin mediates strong antitumor effects. Mol. Pharm. 12, 2544-2550
53. Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., Parish, M., Murphy, R. E., Del Rosario, J., Oates, B. D., Lai, J. Y., Matin, M. J., Ainekulu, Z., Bhat, A., Bradshaw, C. W., Woodnutt, G., Lerner, R. A., and Lappe, R. W. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 107, 22611-22616
54. Peng, L., Liu, R., Marik, J., Wang, X., Takada, Y., and Lam, K. S. (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2, 381-389
55. Wuellner, U., Gavrilyuk, J. I., and Barbas, C. F., 3rd (2010) Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics. Angew. Chem. Int. Ed. Engl. 49, 5934-5937
56. List, B., Barbas C. F., 3rd, and Lerner, R. A. (1998) Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis. Proc. Natl. Acad. Sci. U.S.A. 95, 15351-15355
57. Almåsbak, H., Rian, E., Hoel, H. J., Pulè, M., Wälchli, S., Kvalheim, G., Gaudernack, G., and Rasmussen, A. M. (2011) Transiently redirected T cells for adoptive transfer. Cytotherapy 13, 629-640
58. Sinha, S. C., Das, S., Li, L. S., Lerner, R. A., and Barbas, C. F., 3rd (2007) Preparation of integrin α(v)β3-targeting Ab 38C2 constructs. Nat. Protoc. 2, 449-456